The interdisciplinary research of nanotechnology and biomedical application yields an emerging field of nanomedicine, which seeks to develop functional agents for in vivo bioimaging (diagnosis), advanced drug delivery, and innovative therapy. Optical bioimaging techniques demonstrate advantages of low-cost, portability, and non-invasiveness. The biggest challenge for in vivo optical bioimaging is the scattering light background that limits the depth of bioimaging. Recently, new bioimaging techniques that hybridize ultrasound and optics have attracted increasing attention, and deep-tissue high-resolution bioimaging has been conceived in a number of proof-of-concept studies.
Nanomedicine for bioimaging is a contrast agent modified with functional moieties to target a specific part-of-interest, such as cancer cells or tumor tissues. Valuable in situ diagnostic information can be obtained only when both the bioimaging nanomedicine and the ultrasound-optical hybrid system are communicating. Subsequently, a secondary nanomedicine that contains a therapeutic or regenerative drug will be deployed to the part-of-interest, and the drug release could be triggered precisely by non-invasive means, such as ultrasound, optics, magnet, or heat. In a best-case scenario, the therapy or regeneration process can be monitored real-time through the bioimaging. The interactive cooperation between these two procedures will provide accurate and effective treatment for human diseases.
This Research Topic will focus on the development of nanomedicines for deep-tissue high-resolution bioimaging and for non-invasive drug delivery and tissue regeneration. Specifically, the scope will include the development of nano-biomaterials serving as contract agents or drug-delivery agents, and of biomedical instrumentation used for revealing 2D or 3D imaging information or for triggering the drug release and monitoring the effectiveness. Manuscripts, either original research articles or review articles, on the above-mentioned fields are welcome, as well as on the nanodevice for in vivo biosensing, diagnostic, and therapeutic application.
Dr Ming-Yuan Wei currently holds a pending U.S. Patent Application entitled "Systems and Methods for High-Resolution Imaging". All other Guest Editors have no other competing interests to declare with regards to the Topic subject.
The interdisciplinary research of nanotechnology and biomedical application yields an emerging field of nanomedicine, which seeks to develop functional agents for in vivo bioimaging (diagnosis), advanced drug delivery, and innovative therapy. Optical bioimaging techniques demonstrate advantages of low-cost, portability, and non-invasiveness. The biggest challenge for in vivo optical bioimaging is the scattering light background that limits the depth of bioimaging. Recently, new bioimaging techniques that hybridize ultrasound and optics have attracted increasing attention, and deep-tissue high-resolution bioimaging has been conceived in a number of proof-of-concept studies.
Nanomedicine for bioimaging is a contrast agent modified with functional moieties to target a specific part-of-interest, such as cancer cells or tumor tissues. Valuable in situ diagnostic information can be obtained only when both the bioimaging nanomedicine and the ultrasound-optical hybrid system are communicating. Subsequently, a secondary nanomedicine that contains a therapeutic or regenerative drug will be deployed to the part-of-interest, and the drug release could be triggered precisely by non-invasive means, such as ultrasound, optics, magnet, or heat. In a best-case scenario, the therapy or regeneration process can be monitored real-time through the bioimaging. The interactive cooperation between these two procedures will provide accurate and effective treatment for human diseases.
This Research Topic will focus on the development of nanomedicines for deep-tissue high-resolution bioimaging and for non-invasive drug delivery and tissue regeneration. Specifically, the scope will include the development of nano-biomaterials serving as contract agents or drug-delivery agents, and of biomedical instrumentation used for revealing 2D or 3D imaging information or for triggering the drug release and monitoring the effectiveness. Manuscripts, either original research articles or review articles, on the above-mentioned fields are welcome, as well as on the nanodevice for in vivo biosensing, diagnostic, and therapeutic application.
Dr Ming-Yuan Wei currently holds a pending U.S. Patent Application entitled "Systems and Methods for High-Resolution Imaging". All other Guest Editors have no other competing interests to declare with regards to the Topic subject.
